Document Detail

The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.
MedLine Citation:
PMID:  2674335     Owner:  NLM     Status:  MEDLINE    
The relationship between hormone receptor status and the effect of adjuvant tamoxifen in early breast cancer remains controversial. This article presents the results of a randomized trial of adjuvant tamoxifen (40 mg daily for 2 years) versus no adjuvant endocrine therapy in postmenopausal patients. During 1976 to 1984, 1,407 patients were included in the study. Of these, 427 (30%) had high-risk tumors (pN + or pT greater than 30 mm) and were included in a concurrent randomized comparison of postoperative radiotherapy versus adjuvant polychemotherapy. The mean follow-up time was 61/2 years. Tamoxifen improved the recurrence-free survival (RFS) (P less than .01), but the overall survival difference in favor of the tamoxifen-allocated patients was not significant. Data on estrogen (ER) and progesterone receptor (PgR) content were available in 750 patients. Their mean follow-up time was 41/2 years. The effect of tamoxifen was significantly related to ER level (P less than .01). No benefit with tamoxifen was observed among ER-negative patients. The relation to PgR level was of borderline significance (P = .06). Multivariate analysis indicated that most of the interaction between treatment and receptor content was explained by the interaction with ER (P less than .01). The PgR status appeared to modify the effect of tamoxifen among the ER-positive patients and the greatest effect was observed among patients who were positive for both receptors. However, the additional predictive information provided by the PgR assay did not help to identify an unresponsive subgroup of patients.
L E Rutqvist; B Cedermark; T Fornander; U Glas; H Johansson; B Nordenskjöld; S Rotstein; L Skoog; A Somell; T Theve
Related Documents :
20574415 - Lessons for pharmacogenomics studies: association study between cyp2d6 genotype and tam...
2961355 - Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
8455065 - A phase ii evaluation of tamoxifen in unresectable or refractory meningiomas: a southwe...
1021225 - Antiestrogen-induced remissions in stage iv breast cancer.
10487545 - High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophagea...
23269765 - Nail toxicity associated with paclitaxel treatment for ovarian cancer.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  7     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  1989 Oct 
Date Detail:
Created Date:  1989-10-26     Completed Date:  1989-10-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1474-84     Citation Subset:  IM    
Radiumhemmet, Department of Surgery, Karolinska Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / mortality,  therapy*
Clinical Trials as Topic
Combined Modality Therapy
Cyclophosphamide / administration & dosage
Fluorouracil / administration & dosage
Methotrexate / administration & dosage
Middle Aged
Neoplasm Recurrence, Local / prevention & control
Random Allocation
Receptors, Estrogen / drug effects*
Receptors, Progesterone / drug effects*
Tamoxifen / therapeutic use*
Reg. No./Substance:
0/CMF regimen; 0/Receptors, Estrogen; 0/Receptors, Progesterone; 10540-29-1/Tamoxifen; 50-18-0/Cyclophosphamide; 51-21-8/Fluorouracil; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian ...
Next Document:  Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the ...